ellaOne

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

ulipristal

Disponible depuis:

Laboratoire HRA Pharma

Code ATC:

G03AD02

DCI (Dénomination commune internationale):

ulipristal acetate

Groupe thérapeutique:

Sex hormones and modulators of the genital system, , Emergency contraceptives

Domaine thérapeutique:

Contraception, Postcoital

indications thérapeutiques:

Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

Descriptif du produit:

Revision: 30

Statut de autorisation:

Authorised

Date de l'autorisation:

2009-05-15

Notice patient

                                37
B. PACKAGE LEAFLET
38
PACKAGE LEAFLET: INFORMATION FOR THE USER
ELLAONE 30 MG TABLET
Ulipristal acetate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your pharmacist, doctor or other
healthcare professional has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your pharmacist, doctor, or other
healthcare professional.
This includes any possible side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What ellaOne is and what it is used for
2.
What you need to know before you take ellaOne
3.
How to take ellaOne
4.
Possible side effects
5.
How to store ellaOne
6.
Contents of the pack and other information
- Useful information about contraception
1.
WHAT ELLAONE IS AND WHAT IT IS USED FOR
ellaOne is an emergency contraceptive
ellaOne is a contraceptive intended to prevent pregnancy after
unprotected sex or if your contraceptive
method has failed. For example:
-
if you had sex without protection;
-
if your or your partner’s condom tore, slipped or came off, or if
you forgot to use one;
-
if you did not take your contraceptive pill as recommended.
You should take the tablet as soon as possible after sex, and within a
maximum of 5 days (120 hours).
This is because it is more effective if you take it as soon as
possible after unprotected sex.
This medicine is suitable for any woman of childbearing age, including
adolescents.
You can take the tablet at any time in the menstrual cycle.
ellaOne does not work if you are already pregnant
If your menstrual period is late, there is a possibility that you may
be pregnant. When your period is
late or when you have symptoms of pregnancy (heavy breasts, morning
sickness) you should consult a
doctor or other healthcare professional before taking the tablet.
If you have unprotected sex after taki
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ellaOne 30 mg tablet
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 30 mg ulipristal acetate.
Excipients with known effect
Each tablet contains 237 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
White to marble creamy, round curved tablet of 9 mm diameter engraved
with
_“еllа”_
on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Emergency contraception within 120 hours (5 days) of unprotected
sexual intercourse or contraceptive
failure.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The treatment consists of one tablet to be taken orally as soon as
possible, but no later than 120 hours
(5 days) after unprotected intercourse or contraceptive failure.
The tablet can be taken at any time during the menstrual cycle.
If vomiting occurs within 3 hours of the tablet intake, another tablet
should be taken.
If a woman’s menstrual period is late or in case of symptoms of
pregnancy, pregnancy should be
excluded before the tablet is administered.
_Special populations_
_ _
_Renal impairment_
No dose adjustment is necessary.
_Hepatic impairment _
In the absence of specific studies, no alternate dose recommendations
for ulipristal acetate can be
made.
_Severe hepatic impairment_
In the absence of specific studies, ulipristal acetate is not
recommended.
_Paediatric population _
There is no relevant use of ulipristal acetate for children of
prepubertal age in the indication
emergency contraception
_. _
3
Adolescents:
ulipristal acetate for emergency contraception is suitable for any
woman of child bearing age,
including adolescents. No differences in safety or efficacy have been
shown compared to adult women
aged 18 and older (see section 5.1).
Method of administration
Oral use.
The tablet can be taken with or without food.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1
4.4
SPECI
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation bulgare 06-02-2015
Notice patient Notice patient espagnol 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation espagnol 06-02-2015
Notice patient Notice patient tchèque 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation tchèque 06-02-2015
Notice patient Notice patient danois 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation danois 06-02-2015
Notice patient Notice patient allemand 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation allemand 06-02-2015
Notice patient Notice patient estonien 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation estonien 06-02-2015
Notice patient Notice patient grec 26-01-2024
Notice patient Notice patient français 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation français 06-02-2015
Notice patient Notice patient italien 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation italien 06-02-2015
Notice patient Notice patient letton 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation letton 06-02-2015
Notice patient Notice patient lituanien 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation lituanien 06-02-2015
Notice patient Notice patient hongrois 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation hongrois 06-02-2015
Notice patient Notice patient maltais 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation maltais 06-02-2015
Notice patient Notice patient néerlandais 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation néerlandais 06-02-2015
Notice patient Notice patient polonais 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation polonais 06-02-2015
Notice patient Notice patient portugais 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation portugais 06-02-2015
Notice patient Notice patient roumain 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation roumain 06-02-2015
Notice patient Notice patient slovaque 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation slovaque 06-02-2015
Notice patient Notice patient slovène 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation slovène 06-02-2015
Notice patient Notice patient finnois 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation finnois 06-02-2015
Notice patient Notice patient suédois 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation suédois 06-02-2015
Notice patient Notice patient norvégien 26-01-2024
Notice patient Notice patient islandais 26-01-2024
Notice patient Notice patient croate 26-01-2024
Rapport public d'évaluation Rapport public d'évaluation croate 06-02-2015

Rechercher des alertes liées à ce produit

Afficher l'historique des documents